Related references
Note: Only part of the references are listed.Is stiripentol truly effective for treating primary hyperoxaluria?
Cristina Martin-Higueras et al.
CLINICAL KIDNEY JOURNAL (2021)
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study
Bernd Hoppe et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Lumasiran: First Approval
Lesley J. Scott et al.
DRUGS (2021)
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias
Maria Dolores Moya-Garzon et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
Gema Ariceta et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 A Placebo-Controlled Randomized Clinical Trial
Yaacov Frishberg et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Caroline Kempf et al.
PEDIATRIC NEPHROLOGY (2020)
ALLN-177, oral enzyme therapy for hyperoxaluria
James E. Lingeman et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning
Marine Le Dudal et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology
Julie Esteve et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Molecular basis of primary hyperoxaluria: clues to innovative treatments
Mirco Dindo et al.
UROLITHIASIS (2019)
A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
Dawn Milliner et al.
UROLITHIASIS (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
Bernd Hoppe et al.
PEDIATRIC NEPHROLOGY (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure
Fang Zhao et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Primary Hyperoxaluria
Pierre Cochat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome
Jerome Harambat et al.
KIDNEY INTERNATIONAL (2010)
Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1
Sonia Fargue et al.
KIDNEY INTERNATIONAL (2009)